Product Description
TRK-750 is being developed by Toray Industries for the treatment of patients with Chemotherapy-induced Peripheral Neuropathy. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04282590?term=TRK-750&draw=2&rank=1)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Toray Industries
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Chemotherapy-induced Peripheral Neuropathy|Peripheral Nervous System Diseases
Phase 1: Neuralgia|Neuropathic Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2019-003561-17 | P2 |
Unknown status |
Chemotherapy-induced Peripheral Neuropathy |
2022-05-20 |
|
| Chopin Study | P2 |
Withdrawn |
Peripheral Nervous System Diseases|Chemotherapy-induced Peripheral Neuropathy |
2021-12-01 |
32% |
| 750P1C01 | P1 |
Completed |
Neuralgia|Neuropathic Pain |
2018-08-31 |